Gritstone bio is a leading brand in the development of next-generation vaccines for cancer and infectious diseases. Their unique approach focuses on generating a therapeutic immune response by targeting select antigens, leveraging insights into the immune system's ability to recognize and destroy diseased cells. Initially specializing in tumor-specific neoantigens, Gritstone bio has expanded its programs to include viral antigens displayed on the surface of virally infected cells.

This approach is based on the common biology underlying immune system recognition in both anti-tumor and anti-viral immunity. Gritstone bio believes that activating and directing the immune system to these targets can offer significant benefits in immunotherapy for a wider range of patients. Headquartered in Emeryville, California, with key functions in Cambridge, Massachusetts, and Pleasanton, California, Gritstone bio is led by an experienced leadership team with expertise in immunotherapy research, genomics and bioinformatics, clinical and regulatory development, and biomanufacturing.

With their innovative approach, Gritstone bio is paving the way for groundbreaking advancements in the field of immunotherapy